These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 15584487)

  • 1. IFN-beta treatment modulates the CD28/CTLA-4-mediated pathway for IL-2 production in patients with relapsing-remitting multiple sclerosis.
    Espejo C; Brieva L; Ruggiero G; Río J; Montalban X; Martínez-Cáceres EM
    Mult Scler; 2004 Dec; 10(6):630-5. PubMed ID: 15584487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of interferon-beta on co-signaling molecules: upregulation of CD40, CD86 and PD-L2 on monocytes in relation to clinical response to interferon-beta treatment in patients with multiple sclerosis.
    Wiesemann E; Deb M; Trebst C; Hemmer B; Stangel M; Windhagen A
    Mult Scler; 2008 Mar; 14(2):166-76. PubMed ID: 17942524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis.
    Schreiner B; Mitsdoerffer M; Kieseier BC; Chen L; Hartung HP; Weller M; Wiendl H
    J Neuroimmunol; 2004 Oct; 155(1-2):172-82. PubMed ID: 15342209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunomodulatory effects of IFN-beta1a treatment alone or associated with pentoxifylline in patients with relapsing-remitting multiple sclerosis (RRMS).
    Pede PD; Visintini D; Telera A; Cucurachi L; Campanini C; Immovilli P; Vescovini R; Sansoni P
    J Interferon Cytokine Res; 2005 Aug; 25(8):485-9. PubMed ID: 16108731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of combination therapy of beta-interferon 1a and prednisone on serum immunologic markers in patients with multiple sclerosis.
    Salama HH; Kolar OJ; Zang YC; Zhang J
    Mult Scler; 2003 Feb; 9(1):28-31. PubMed ID: 12617264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glatiramer acetate and IFN-beta act on dendritic cells in multiple sclerosis.
    Hussien Y; Sanna A; Söderström M; Link H; Huang YM
    J Neuroimmunol; 2001 Dec; 121(1-2):102-10. PubMed ID: 11730946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IFN-β induces the proliferation of CD4+CD25+Foxp3+ regulatory T cells through upregulation of GITRL on dendritic cells in the treatment of multiple sclerosis.
    Chen M; Chen G; Deng S; Liu X; Hutton GJ; Hong J
    J Neuroimmunol; 2012 Jan; 242(1-2):39-46. PubMed ID: 22112394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of combined IFNbeta-1a and glatiramer acetate therapy on GA-specific T-cell responses in multiple sclerosis.
    Dhib-Jalbut S; Chen M; Henschel K; Ford D; Costello K; Panitch H
    Mult Scler; 2002 Dec; 8(6):485-91. PubMed ID: 12474988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon-beta treatment in multiple sclerosis patients decreases the number of circulating T cells producing interferon-gamma and interleukin-4.
    Furlan R; Bergami A; Lang R; Brambilla E; Franciotta D; Martinelli V; Comi G; Panina P; Martino G
    J Neuroimmunol; 2000 Nov; 111(1-2):86-92. PubMed ID: 11063825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-beta in vitro and in vivo: rationale for the therapy of multiple sclerosis.
    Mitsdoerffer M; Schreiner B; Kieseier BC; Neuhaus O; Dichgans J; Hartung HP; Weller M; Wiendl H
    J Neuroimmunol; 2005 Feb; 159(1-2):155-64. PubMed ID: 15652415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. VLA-4/CD49d downregulated on primed T lymphocytes during interferon-beta therapy in multiple sclerosis.
    Muraro PA; Leist T; Bielekova B; McFarland HF
    J Neuroimmunol; 2000 Nov; 111(1-2):186-94. PubMed ID: 11063837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B cells as a therapeutic target for IFN-β in relapsing-remitting multiple sclerosis.
    Ramgolam VS; Sha Y; Marcus KL; Choudhary N; Troiani L; Chopra M; Markovic-Plese S
    J Immunol; 2011 Apr; 186(7):4518-26. PubMed ID: 21368231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of differentiation and functional properties of monocytes and monocyte-derived dendritic cells by interferon beta in multiple sclerosis.
    Zang YC; Skinner SM; Robinson RR; Li S; Rivera VM; Hutton GJ; Zhang JZ
    Mult Scler; 2004 Oct; 10(5):499-506. PubMed ID: 15471364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD28 ligation in the absence of TCR stimulation up-regulates IL-17A and pro-inflammatory cytokines in relapsing-remitting multiple sclerosis T lymphocytes.
    Camperio C; Muscolini M; Volpe E; Di Mitri D; Mechelli R; Buscarinu MC; Ruggieri S; Piccolella E; Salvetti M; Gasperini C; Battistini L; Tuosto L
    Immunol Lett; 2014; 158(1-2):134-42. PubMed ID: 24412596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b.
    Ochi H; Feng-Jun M; Osoegawa M; Minohara M; Murai H; Taniwaki T; Kira J
    J Neurol Sci; 2004 Jul; 222(1-2):65-73. PubMed ID: 15240198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-10 and interleukin-12 modulation in patients with relapsing-remitting multiple sclerosis on therapy with interferon-beta 1a: differences in responders and non responders.
    Carrieri PB; Ladogana P; Di Spigna G; de Leva MF; Petracca M; Montella S; Buonavolontà L; Florio C; Postiglione L
    Immunopharmacol Immunotoxicol; 2008; 30(4):1-9. PubMed ID: 18686100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon-beta up-regulates the expression of co-stimulatory molecules CD80, CD86 and CD40 on monocytes: significance for treatment of multiple sclerosis.
    Marckmann S; Wiesemann E; Hilse R; Trebst C; Stangel M; Windhagen A
    Clin Exp Immunol; 2004 Dec; 138(3):499-506. PubMed ID: 15544628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The 'immunological-synapse' at its APC side in relapsing and secondary-progressive multiple sclerosis: modulation by interferon-beta.
    Shapiro S; Galboiz Y; Lahat N; Kinarty A; Miller A
    J Neuroimmunol; 2003 Nov; 144(1-2):116-24. PubMed ID: 14597105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IFN-beta1a and IFN-beta1b have different patterns of influence on cytokines.
    Sega S; Wraber B; Mesec A; Horvat A; Ihan A
    Clin Neurol Neurosurg; 2004 Jun; 106(3):255-8. PubMed ID: 15177779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dysregulated neurotrophin mRNA production by immune cells of patients with relapsing remitting multiple sclerosis.
    Urshansky N; Mausner-Fainberg K; Auriel E; Regev K; Farhum F; Karni A
    J Neurol Sci; 2010 Aug; 295(1-2):31-7. PubMed ID: 20541775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.